On April 6, 2010, the FDA granted approval to a generic formulation of zidovudine injection USP, 10 mg/mL, packaged in 200 mg/20 mL single-use vials, manufactured by Pharmaforce, Inc., of Columbus, OH. FDA has determined that the generic formulation is bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Retrovir® IV Infusion, 10 mg/mL, of VIIV Healthcare Co.
Health care providers have been constantly amazed at the variation in response to infection with HIV-1. In our clinic, we now routinely see elderly patients who have been on various antiretroviral regimens over the years but still persist with high CD4 counts and low viral loads. They are truly long-term non-progressors.
Investigators of HIV among teenagers and young adults need to develop additional and sometimes complex strategies for enrolling trial participants.
One of the hottest topics in critical care these days is whether all ICUs should be staffed around the clock, seven days a week (24/7), by physicians with special training and qualifications in critical care (intensivists).
The use of a rapid response system (RRS), or medical emergency team (MET), has become established as a patient safety measure to ensure early detection of patient compromise.
This issue deals with two key topics in the ongoing discussion about how critical care should be organized: rapid response systems (also called medical emergency teams or rapid response teams) for identifying patients not in ICUs who are at risk for life-threatening deterioration, and around-the-clock intensivist staffing in the ICU.